6 September 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at today’s Annual General Meeting were duly passed.

Read more…

6 September 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.

Read more…

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its Annual Report and Accounts for the year ended 31 March 2016 and the Notice of the 2016 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.

Read more…

Published long term Phase I data show evidence of improvements in neurological function sustained out to 24 months and good safety profile.

Read more…

ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer-reviewed scientific journal of further key pre-clinical efficacy data with its human retinal progenitor cells (hRPCs). A Phase I/II clinical trial has recently commenced in the US to evaluate the safety, tolerability and preliminary efficacy of the hRPCs in patients with the inherited blindness-causing disease, retinitis pigmentosa (RP).

Read more..

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2016.

Read more..

Pencoed, UK, 9 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has selected glioblastoma multiforme (“GBM”) as the first clinical target for its exosome nanomedicine platform, based on evidence of tumour-inhibiting activity from early pre-clinical studies with the technology.

Read more…

Pencoed, UK, 14 June 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2016 on Thursday 7 July 2016.

Read More..

Pencoed, UK, 13 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with its stroke programme.  The Company has completed patient recruitment in the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate in patients with motor disability as a result of ischaemic stroke.

Read More..